Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis

NCT03896295 is registered in ClinicalTrials.gov with Momenta Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03896295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03896295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
Lead sponsor
Momenta Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
August 6, 2019
Completion date
December 9, 2020
Enrollment
37 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis